Bioavailable curcumin (CurcuBoost®) as an adjunct therapy for liver dysfunction: a randomized controlled study

Authors

  • Deepti Gupta Department of Medicine, Tulsi Multispecialty Hospital, Delhi, India
  • Devesh Kumar Department of Clinical Operations, IR Innovate Research Pvt. Ltd., Noida, Uttar Pradesh, India

DOI:

https://doi.org/10.18203/2319-2003.ijbcp20263787

Keywords:

Curcumin, Curcuminoids, CurcuBoost, Hepatoprotection, Liver dysfunction, Liver enzymes, Non-alcoholic fatty liver disease

Abstract

Background: Chronic liver dysfunction is associated with persistent liver enzyme elevations, hepatocellular injury and impaired quality of life. Curcumin has demonstrated hepatoprotective properties. This study aimed to evaluate the efficacy, safety and tolerability of CurcuBoost®, a bioavailable curcumin formulation, as an adjunct to standard of care (SOC) in adults with deranged liver function.

Methods: In this randomized, open-label, parallel-group trial, 50 adults with biochemical evidence of liver dysfunction were randomized (1:1) to CurcuBoost® (500 mg orally) plus SOC or SOC alone for 12 weeks. The primary endpoint was change in serum liver enzymes from baseline to Week 12. Secondary endpoints included changes in liver disease quality of life (LDQOL) scores and safety outcomes. Analyses used a modified intention-to-treat approach with ANCOVA.

Results: All 50 participants completed the study. Compared with SOC alone (n=25), CurcuBoost® plus SOC (n=25) produced greater reductions in alanine aminotransferase (−109.72 vs −93.39 IU/l; p=0.0012), aspartate aminotransferase (−107.07 vs −86.81 IU/l; p=0.0001), alkaline phosphatase (−354.42 vs −311.75 IU/l; p<0.0001) and gamma-glutamyl transferase (−44.46 vs −38.78 IU/l; p=0.0364) at Week 12. Total bilirubin also decreased significantly more with CurcuBoost® (p=0.0008), while renal function remained stable. LDQOL scores improved in both groups, with greater improvement in the CurcuBoost® plus SOC group (p<0.0001). No serious adverse events were reported.

Conclusions: Adjunctive treatment with CurcuBoost® significantly improved liver enzyme profiles and liver-related quality of life compared with standard of care alone, with an excellent safety profile.

Metrics

Metrics Loading ...

References

Zhang Y, Luo M, Ming Y. Global burden of cirrhosis and other chronic liver diseases caused by specific etiologies from 1990 to 2021. BMC Gastroenterol. 2025;25:641. DOI: https://doi.org/10.1186/s12876-025-04264-5

Natarajan T, Shenbaga LS, Lakshminarayanan S, Madhavan B, Ravichandran DK, Prasanth K. Assessment of liver enzymes and the risk of non-alcoholic fatty liver disease (NAFLD) among information technology (IT) professionals. Cureus. 2025;17:88786. DOI: https://doi.org/10.7759/cureus.88786

Rahmani J, Miri A, Namjoo I, Zamaninour N, Maljaei MB, Zhou K, et al. Elevated liver enzymes and cardiovascular mortality: a systematic review and dose-response meta-analysis of more than one million participants. Eur J Gastroenterol Hepatol. 2019;31:555-62. DOI: https://doi.org/10.1097/MEG.0000000000001353

Kunutsor SK, Apekey TA, Seddoh D, Walley J. Liver enzymes and risk of all-cause mortality in general populations: a systematic review and meta-analysis. Int J Epidemiol. 2014;43:187-201. DOI: https://doi.org/10.1093/ije/dyt192

Tamber SS, Bansal P, Sharma S, Singh RB, Sharma R. Biomarkers of liver diseases. Mol Biol Rep. 2023;50:7815-23. DOI: https://doi.org/10.1007/s11033-023-08666-0

Jeznach-Steinhagen A, Ostrowska J, Czerwonogrodzka-Senczyna A, Boniecka I, Shahnazaryan U, Kuryłowicz A. Dietary and pharmacological treatment of nonalcoholic fatty liver disease. Medicina. 2019;55:166. DOI: https://doi.org/10.3390/medicina55050166

Cho K, Park S, Koyanagi A, Jacob L, Yon DK, Lee SW, et al. The effect of pharmacological treatment and lifestyle modification in patients with nonalcoholic fatty liver disease: an umbrella review of meta-analyses of randomized controlled trials. Obes Rev. 2022;23:e13464. DOI: https://doi.org/10.1111/obr.13464

Fu Y, Zhou Y, Shen L, Li X, Zhang H, Cui Y, et al. Diagnostic and therapeutic strategies for non-alcoholic fatty liver disease. Front Pharmacol. 2022;13:973366. DOI: https://doi.org/10.3389/fphar.2022.973366

Farzaei MH, Zobeiri M, Parvizi F, El-Senduny FF, Marmouzi I, Coy-Barrera E, et al. Curcumin in liver diseases: a systematic review of the cellular mechanisms of oxidative stress and clinical perspective. Nutrients. 2018;10:855. DOI: https://doi.org/10.3390/nu10070855

Chu YH, Pang BY, Yang M, Meng Q, Leng Y. The intervention of curcumin on rodent models of hepatic fibrosis: a systematic review and meta-analysis. PLoS One. 2024;19:e0304176. DOI: https://doi.org/10.1371/journal.pone.0304176

Samuhasaneeto S, Thong-Ngam D, Kulaputana O, Suyasunanont D, Klaikeaw N. Curcumin decreased oxidative stress, inhibited NF-κB activation and improved liver pathology in ethanol-induced liver injury in rats. J Biomed Biotechnol. 2009;2009:981963. DOI: https://doi.org/10.1155/2009/981963

Obrzut O, Gostyńska-Stawna A, Kustrzyńska K, Stawny M, Krajka-Kuźniak V. Curcumin: a natural warrior against inflammatory liver diseases. Nutrients. 2025;17:1373. DOI: https://doi.org/10.3390/nu17081373

Vajdi M, Hassanizadeh S, Hassanizadeh R, Bagherniya M. Curcumin supplementation effect on liver enzymes in patients with nonalcoholic fatty liver disease: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. Nutr Rev. 2025;83:1-12. DOI: https://doi.org/10.1093/nutrit/nuad166

Dehzad MJ, Ghalandari H, Amini MR, Askarpour M. Effects of curcumin/turmeric supplementation on liver function in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials. Complement Ther Med. 2023;74:102952. DOI: https://doi.org/10.1016/j.ctim.2023.102952

Molani-Gol R, Dehghani A, Rafraf M. Effects of curcumin/turmeric supplementation on the liver enzymes, lipid profiles, glycemic index and anthropometric indices in non-alcoholic fatty liver patients: an umbrella meta-analysis. Phytother Res. 2024;38:539-55. DOI: https://doi.org/10.1002/ptr.8051

Saadati S, Sadeghi A, Mansour A, Yari Z, Poustchi H, Hedayati M, et al. Curcumin and inflammation in non-alcoholic fatty liver disease: a randomized, placebo-controlled clinical trial. BMC Gastroenterol. 2019;19:133. DOI: https://doi.org/10.1186/s12876-019-1055-4

Yaikwawong M, Kamdee K, Chuengsamarn S. Curcumin attenuates liver steatosis via antioxidant and anti-inflammatory pathways in obese patients with type 2 diabetes mellitus: a randomized controlled trial. Int J Mol Sci. 2025;26:9286. DOI: https://doi.org/10.3390/ijms26199286

White CM, Lee JY. The impact of turmeric or its curcumin extract on nonalcoholic fatty liver disease: a systematic review of clinical trials. Pharm Pract (Granada). 2019;17:1350. DOI: https://doi.org/10.18549/PharmPract.2019.1.1350

Yaikwawong M, Jansarikit L, Jirawatnotai S, Chuengsamarn S. Curcumin for inflammation control in individuals with type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease: a randomized controlled trial. Nutrients. 2025;17:1972. DOI: https://doi.org/10.3390/nu17121972

Mokgalaboni K, Ntamo Y, Ziqubu K, Nyambuya TM, Nkambule BB, Mazibuko-Mbeje SE, et al. Curcumin supplementation improves biomarkers of oxidative stress and inflammation in conditions of obesity, type 2 diabetes and NAFLD: updating the status of clinical evidence. Food Funct. 2021;12:12235-49. DOI: https://doi.org/10.1039/D1FO02696H

Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, Abdelmalek MF, Caldwell S, Barb D, et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77:1797-835. DOI: https://doi.org/10.1097/HEP.0000000000000323

Gralnek IM, Hays RD, Kilbourne A, Rosen HR, Keeffe EB, Artinian L, et al. Development and evaluation of the Liver Disease Quality of Life instrument in persons with advanced, chronic liver disease--the LDQOL 1.0. Am J Gastroenterol. 2000;95:3552-65. DOI: https://doi.org/10.1111/j.1572-0241.2000.03375.x

Ebrahimzadeh A, Ebrahimzadeh A, Fooladshekan S, Mohseni S, Mohtashamian A, Babajafari S, et al. Therapeutic effects of curcumin supplementation on liver enzymes of nonalcoholic fatty liver disease patients: a systematic review and meta-analysis of randomized clinical trials. Food Sci Nutr. 2024;13:e4144. DOI: https://doi.org/10.1002/fsn3.4144

Gerami H, Mozaffari-Khosravi H, Mansour A, Sohrabpour AA, Poustchi H, Hashemi Taheri AP, et al. Effect of nano-curcumin supplementation on liver fibrosis in patients with NAFLD-associated fibrosis: a double-blind randomized controlled trial. Sci Rep. 2025;15:38043. DOI: https://doi.org/10.1038/s41598-025-21862-1

Khan H, Ullah H, Nabavi SM. Mechanistic insights of hepatoprotective effects of curcumin: therapeutic updates and future prospects. Food Chem Toxicol. 2019;124:182-91. DOI: https://doi.org/10.1016/j.fct.2018.12.002

Huang BH, Guo ZW, Lv BH, Zhao X, Li YB, Lv WL. A role for curcumin in preventing liver fibrosis in animals: a systematic review and meta-analysis. Front Pharmacol. 2024;15:1396834. DOI: https://doi.org/10.3389/fphar.2024.1396834

Nouri-Vaskeh M, Afshan H, Malek Mahdavi A, Alizadeh L, Fan X, Zarei M. Curcumin ameliorates health-related quality of life in patients with liver cirrhosis: a randomized, double-blind placebo-controlled trial. Complement Ther Med. 2020;49:102351. DOI: https://doi.org/10.1016/j.ctim.2020.102351

Downloads

Published

2026-10-26

How to Cite

Gupta, D., & Kumar, D. (2026). Bioavailable curcumin (CurcuBoost®) as an adjunct therapy for liver dysfunction: a randomized controlled study. International Journal of Basic & Clinical Pharmacology, 15(6), 1333–1340. https://doi.org/10.18203/2319-2003.ijbcp20263787

Issue

Section

Original Research Articles